Studies on the glycemic and lipidemic effect of atenolol and propranolol in normal and diabetic rats.
The effects of the non-selective beta-blocker propranolol (CAS 525-66-6) and the cardioselective drug atenolol (CAS 29122-68-7) on serum glucose, insulin levels and some serum lipid components, were compared in normal and diabetic rats receiving glibenclamide. The two beta-blockers, when administered concurrently with glibenclamide in normal rats, exerted a significant hypoglycemic effect (p < 0.01), while in diabetic rats the two drugs caused a more significant decrease (p < 0.001 and p < 0.01, resp.). Serum insulin levels were mainly unaffected by the two beta-blockers. Propranolol was found to exhibit a hypolipidemic effect in diabetic rats when administered alone or in combination with glibenclamide. In comparison atenolol, when used alone, exerted a significant increase in triglycerides and total lipid levels (p < 0.05) in normal rats. This effect was masked when atenolol was administered concurrently with glibenclamide, but a hypercholesterolemic effect (p < 0.01) was noticed. Paradoxically in diabetic rats, atenolol caused a significant decrease (p < 0.05) in triglycerides level, while its combined use with glibenclamide showed no effect.
Gaafar
K
K
Department of Zoology, Faculty of Science, Cairo University, Giza, Egypt.
Salama
S
S
el Batran
S
S
D000818:Animals; D001262:Atenolol / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood*; D005905:Glyburide / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood*; D008297:Male; D011433:Propranolol / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D014280:Triglycerides; D001262:Atenolol; D002784:Cholesterol; D011433:Propranolol; D005905:Glyburide